Takeda Sells Off Four Diabetes Drugs in $1.25 Billion Deal
Takeda Pharmaceutical is selling off four of its diabetes drugs for $1.25 billion to Tokyo-based Teijin Pharma.
Takeda is divesting itself of the rights to Nesina, Liovel, Inisync, and Zafatek, transferring the assets, marketing rights and eventually marketing authorization associated with the portfolio to Teijin. The four drugs generated about $290 million in sales for Takeda in fiscal year 2019.
The asset transfer will allow Takeda to focus on five key therapeutic areas — gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience.
The move is the company’s latest divesture aimed at decreasing its debt load following its $62 billion acquisition of Shire in 2019.